Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.

Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL.

Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.

2.

No patient left behind: The promise of immune priming with epigenetic agents.

Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR.

Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

3.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

4.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.

Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review. Erratum in: Expert Opin Investig Drugs. 2017 Feb;26(2):261. Carterg, Corey A [corrected to Carter, Corey A].

5.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.

Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

PMID:
27855386
6.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.

Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

7.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.

Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27.

8.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.

Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Review.

9.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.

Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

10.

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.

Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A.

Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032. Review.

11.

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B.

Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.

PMID:
27377482
12.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.

Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.

13.

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

Carter CA, Scicinski JJ, Lybeck HE, Oronsky BT.

Case Rep Oncol. 2016 Apr 23;9(1):246-8. doi: 10.1159/000446064. eCollection 2016 Jan-Apr.

14.

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.

Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.

Discov Med. 2016 Apr;21(116):251-65.

15.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.

Med Oncol. 2016 Jul;33(7):63. doi: 10.1007/s12032-016-0775-3. Epub 2016 May 26.

PMID:
27229330
16.

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Oronsky B, Scicinski J, Cabrales P, Minchinton A.

Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. eCollection 2016.

17.

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.

Discov Med. 2016 Mar;21(115):173-80. Review.

18.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

19.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

20.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

21.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.

Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C.

Case Rep Oncol. 2016 Jan 27;9(1):68-75. doi: 10.1159/000443723. eCollection 2016 Jan-Apr.

22.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.

Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.

23.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.

24.

RRx-001, A novel dinitroazetidine radiosensitizer.

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.

Invest New Drugs. 2016 Jun;34(3):371-7. doi: 10.1007/s10637-016-0326-y. Epub 2016 Feb 3. Review.

25.

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.

Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J.

Oncotarget. 2016 Feb 23;7(8):9041-5. doi: 10.18632/oncotarget.6984.

26.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Neuro Oncol. 2016 Mar;18(3):455-6. doi: 10.1093/neuonc/nov317. Epub 2016 Jan 13. No abstract available.

27.

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.

28.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

29.

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance.

Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P.

Neoplasia. 2015 Sep;17(9):716-722. doi: 10.1016/j.neo.2015.09.001. Review.

30.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR.

Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.

PMID:
26296952
31.

Going viral: a review of replication-selective oncolytic adenoviruses.

Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR.

Oncotarget. 2015 Aug 21;6(24):19976-89. Review.

32.

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R.

Oncotarget. 2015 Aug 28;6(25):21547-56.

33.

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T.

Redox Biol. 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035. Epub 2015 Dec 30.

34.

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.

Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G.

Redox Biol. 2015 Dec;6:1-8. doi: 10.1016/j.redox.2015.07.002. Epub 2015 Jul 2. Review.

35.

Episensitization: Defying Time's Arrow.

Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR.

Front Oncol. 2015 Jun 11;5:134. doi: 10.3389/fonc.2015.00134. eCollection 2015. Review.

36.

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria.

Yalcin O, Oronsky B, Carvalho LJ, Kuypers FA, Scicinski J, Cabrales P.

Malar J. 2015 May 28;14:218. doi: 10.1186/s12936-015-0720-5.

37.

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock.

Brouse C, Ortiz D, Su Y, Oronsky B, Scicinski J, Cabrales P.

Asian J Transfus Sci. 2015 Jan-Jun;9(1):55-60. doi: 10.4103/0973-6247.150952.

38.

The war on cancer: a military perspective.

Oronsky B, Carter CA, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T.

Front Oncol. 2015 Jan 26;4:387. doi: 10.3389/fonc.2014.00387. eCollection 2014. Review.

39.

Rewriting the epigenetic code for tumor resensitization: a review.

Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T.

Transl Oncol. 2014 Oct 24;7(5):626-31. doi: 10.1016/j.tranon.2014.08.003. eCollection 2014 Oct. Review.

40.

Follow the ATP: tumor energy production: a perspective.

Oronsky BT, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, Scicinski JJ.

Anticancer Agents Med Chem. 2014;14(9):1187-98. Review.

PMID:
25102360
41.

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions.

Fens MH, Larkin SK, Oronsky B, Scicinski J, Morris CR, Kuypers FA.

PLoS One. 2014 Jul 9;9(7):e101626. doi: 10.1371/journal.pone.0101626. eCollection 2014.

42.

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

Oronsky B, Oronsky N, Knox S, Fanger G, Scicinski J.

Anticancer Agents Med Chem. 2014;14(8):1121-7. Review.

43.

Development of methods for the bioanalysis of RRx-001 and metabolites.

Scicinski J, Oronsky B, Cooper V, Taylor M, Alexander M, Hadar R, Cosford R, Fleischmann T, Fitch WL.

Bioanalysis. 2014 Apr;6(7):947-56. doi: 10.4155/bio.13.331.

PMID:
24806903
44.

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.

Ning S, Bednarski M, Oronsky B, Scicinski J, Knox SJ.

Biochem Biophys Res Commun. 2014 May 9;447(3):537-42. doi: 10.1016/j.bbrc.2014.04.032. Epub 2014 Apr 13.

PMID:
24735538
45.

The implications of hyponitroxia in cancer.

Oronsky B, Fanger GR, Oronsky N, Knox S, Scicinski J.

Transl Oncol. 2014 Apr;7(2):167-73. doi: 10.1016/j.tranon.2014.02.001. Epub 2014 Mar 4. Review.

46.

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.

Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J.

Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382. eCollection 2014 Jan.

47.

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J.

Theranostics. 2013 May 25;3(6):437-47. doi: 10.7150/thno.5658. Print 2013. Review.

48.

The scarlet letter of alkylation: a mini review of selective alkylating agents.

Oronsky BT, Reid T, Knox SJ, Scicinski JJ.

Transl Oncol. 2012 Aug;5(4):226-9. Epub 2012 Aug 1.

49.

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

Oronsky BT, Scicinski JJ, Reid T, Knox S.

Transl Oncol. 2012 Jun;5(3):133-40. Epub 2012 Jun 1.

50.

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.

Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL.

Drug Metab Dispos. 2012 Sep;40(9):1810-6. doi: 10.1124/dmd.112.046755. Epub 2012 Jun 14.

PMID:
22699395

Supplemental Content

Loading ...
Support Center